Effects of Dietary Sodium and Protein Intake on Glomerular Filtration Rate in Subjects with Type 2 Diabetes Treated with Sodium-Glucose Cotransporter 2 Inhibitors

被引:0
|
作者
Gaudio, Costanza [1 ,2 ]
Seghieri, Marta [3 ,4 ]
Merciai, Chiara [1 ]
Colombi, Claudia [3 ]
Spatoliatore, Giuseppe [1 ]
Baggiore, Cristiana Maria [3 ]
Rosati, Alberto [1 ]
机构
[1] Nuovo San Giovanni Dio Hosp, Nephrol Unit, Florence, Italy
[2] Univ Florence, Dept Biomed Expt & Clin Sci Mario Serio, Florence, Italy
[3] Nuovo San Giovanni Dio Hosp, Diabet Unit, Florence, Italy
[4] Nuovo Osped San Giovanni Dio, Via Torregalli 1, I-50143 Florence, Italy
关键词
SGLT2; inhibitors; estimated GFR; creatinine clearance; salt intake; protein intake; KIDNEY; EMPAGLIFLOZIN; DAPAGLIFLOZIN; DECREASE; OUTCOMES;
D O I
10.1055/a-2041-1516
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Approximately one-fourth of patients treated with sodium-glucose cotransporter 2 inhibitors (SGLT2i) experience an acute estimated glomerular filtration rate (eGFR) reduction of more than 10 % ("dippers"). High sodium and protein intake can increase intraglomerular pressure and predispose to a decline in renal function. We investigated whether measured creatinine clearance (CrCl) is a sensitive enough method to detect the initial dip of GFR and if dietary sodium and protein intake might influence the extent of the early change in GFR. Methods 28 subjects with type 2 diabetes (T2D) were enrolled. For sodium and urea determination, 24-h urinary samples were collected to estimate sodium and protein intake respectively before and 1, 3 and 6 months after SGLT2i initiation. Results Mean CrCl was 83.23 +/- 25.52 mL/min/1.73 m(2) (eGFR 67.32 +/- 16.07) and dropped by 19 % at month 1 (eGFR by 6 %). Dippers were 64 and 40 %, according to CrCl and eGFR, respectively. Exploring the potential correlation between changes in renal function and salt intake,.CrCl and baseline urinary sodium were inversely related at month 1 (r = -0,61; p < 0.01), at month 3 (r = -0.51; p = 0.01) and month 6 (r = -0,48; p < 0.05). Likewise, an inverse correlation between.CrCl and baseline urinary urea was demonstrated at months 1 and 3 (r = -0.46; p < 0.05 for both); at month 6, a similar trend was observed (r = -0.47; p = 0.054). Conclusions The present study suggests that a higher dietary sodium and protein intake may amplify the extent of the early dip in GFR, as detected with measured CrCl, in diabetic patients undergoing SGLT2i treatment.
引用
收藏
页码:254 / 259
页数:6
相关论文
共 50 条
  • [41] The effect of the sodium-glucose cotransporter type-2 inhibitor dapagliflozin on glomerular filtration rate in healthy cats
    Gal, A.
    Burton, S. E.
    Weidgraaf, K.
    Singh, P.
    Lopez-Villalobos, N.
    Jacob, A.
    Malabu, U.
    Burchell, R.
    DOMESTIC ANIMAL ENDOCRINOLOGY, 2020, 70
  • [42] Sodium-Glucose Cotransporter 2 Inhibitors with Renoprotective Effects
    Satirapoj, Bancha
    KIDNEY DISEASES, 2017, 3 (01) : 24 - 32
  • [43] Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Retinopathy in Patients With Type 2 Diabetes
    Yen, Fu-Shun
    Wei, James Cheng-Chung
    Yu, Teng-Shun
    Hung, Yu-Tung
    Hsu, Chih-Cheng
    Hwu, Chii-Min
    JAMA NETWORK OPEN, 2023, 6 (12) : E2348431
  • [44] Sodium-glucose cotransporter 2 inhibitors and death and heart failure in type 2 diabetes
    Yanai, Hidekatsu
    ANNALS OF TRANSLATIONAL MEDICINE, 2017, 5 (23)
  • [45] Sodium-Glucose Cotransporter 2 Inhibitors and Nephrolithiasis Risk in Patients With Type 2 Diabetes
    Paik, Julie M.
    Tesfaye, Helen
    Curhan, Gary C.
    Zakoul, Heidi
    Wexler, Deborah J.
    Patorno, Elisabetta
    JAMA INTERNAL MEDICINE, 2024, 184 (03) : 265 - 274
  • [46] Kidney Disease in Type 2 Diabetes Mellitus and Benefits of Sodium-Glucose Cotransporter 2 Inhibitors: A Consensus Statement
    Roy, Ajitesh
    Maiti, Animesh
    Sinha, Anirban
    Baidya, Arjun
    Basu, Asish Kumar
    Sarkar, Dasarathi
    Sanyal, Debmalya
    Biswas, Dibakar
    Maisnam, Indira
    Pandit, Kaushik
    Raychaudhuri, Moutusi
    Sengupta, Nilanjan
    Chakraborty, Partha Pratim
    Mukhopadhyay, Pradip
    Raychaudhuri, Pradip
    Sahana, Pranab Kumar
    Chatterjee, Purushottam
    Bhattacharjee, Rana
    Dasgupta, Ranen
    Saraogi, Ravi Kant
    Pal, Salil Kumar
    Mukhopadhyay, Sarmishtha
    Mukhopadhyay, Satinath
    Goswami, Soumik
    Chowdhury, Subhankar
    Ghosh, Sujoy
    DIABETES THERAPY, 2020, 11 (12) : 2791 - 2827
  • [47] Sodium-glucose cotransporter-2 inhibitors and risk for genitourinary infections in older adults with type 2 diabetes
    Varshney, Navya
    Billups, Sarah J.
    Saseen, Joseph J.
    Fixen, Cy W.
    THERAPEUTIC ADVANCES IN DRUG SAFETY, 2021, 12
  • [48] Diabetic Ketoacidosis in Patients with Type 2 Diabetes on Sodium-glucose Cotransporter-2 Inhibitors - A Case Series
    Sharma, Purva V.
    Jobanputra, Yash B.
    Lewin, Karen
    Bagatell, Stuart
    Lichtstein, Daniel M.
    REVIEWS ON RECENT CLINICAL TRIALS, 2018, 13 (02) : 156 - 160
  • [49] Sodium-glucose cotransporter inhibitors in type 2 diabetes: thinking beyond glucose lowering
    Neuen, Brendon L.
    Cherney, David Z.
    Jardine, Meg J.
    Perkovic, Vlado
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2019, 191 (41) : E1128 - E1135
  • [50] Considerations and possibilities for sodium-glucose cotransporter 2 inhibitors in pediatric CKD
    Kula, Alexander J.
    PEDIATRIC NEPHROLOGY, 2022, 37 (10) : 2267 - 2276